Strontium ranelate

Strontium ranelate
Clinical data
Trade names	Protelos, Osseor
AHFS/Drugs.com	UK Drug Information
License data	EU EMA: by INN;
Pregnancy; category	Only intended for use in postmenopausal women, no data on exposed pregnancies. If strontium ranelate is used inadvertently during pregnancy, treatment must be stopped.;
Routes of; administration	By mouth
ATC code	M05BX03 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only);
Pharmacokinetic data
Bioavailability	25% (range 19–27%)
Protein binding	25% for plasma protein and high affinity for bone tissue
Metabolism	As a divalent cation, strontium is not metabolised. Does not inhibit cytochrome P450 enzymes
Elimination half-life	60 hours
Excretion	Renal and gastrointestinal. Plasma clearance is about 12 ml/min (CV 22%) and renal clearance about 7 ml/min (CV 28%)
Identifiers
	IUPAC name distrontium 5-[bis(2-oxido-2-oxoethyl)amino]-4-cyano-; 3-(2-oxido-2-oxoethyl)thiophene-2-carboxylate;
CAS Number	135459-87-9 ;
PubChem CID	6918182;
ChemSpider	5293393 ;
UNII	04NQ160FRU;
KEGG	D08468 ;
CompTox Dashboard (EPA)	DTXSID40872400 ;
ECHA InfoCard	100.218.275
Chemical and physical data
Formula	C12H6N2O8SSr2
Molar mass	513.49 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [Sr+2].[Sr+2].O=C([O-])CN(c1sc(c(c1C#N)CC([O-])=O)C([O-])=O)CC([O-])=O;
	InChI InChI=1S/C12H10N2O8S.2Sr/c13-2-6-5(1-7(15)16)10(12(21)22)23-11(6)14(3-8(17)18)4-9(19)20;;/h1,3-4H2,(H,15,16)(H,17,18)(H,19,20)(H,21,22);;/q;2*+2/p-4 ; Key:XXUZFRDUEGQHOV-UHFFFAOYSA-J ;
	(what is this?) (verify)

Strontium ranelate, a strontium(II) salt of ranelic acid, is a medication for osteoporosis marketed as Protelos or Protos by Servier. Studies indicate it can also slow the course of osteoarthritis of the knee. The drug is unusual in that it both increases deposition of new bone by osteoblasts and reduces the resorption of bone by osteoclasts. It is therefore promoted as a "dual action bone agent" (DABA).

On 13 May 2013, Servier released a Direct Healthcare Professional Communication which stated that new restrictions for the use of strontium ranelate are now in place, as randomised trials have shown an increased risk of myocardial infarction. Servier states that the use is now restricted to treatment of severe osteoporosis in postmenopausal women at high risk for fracture. The European Pharmacovigilance Risk Assessment Committee (PRAC) recommended restriction in the use of strontium ranelate, based on a routine benefit-risk assessment of the medicine, which included data showing a possible increased risk of heart problems, including heart attacks. On 21 February 2014 the European Medicine Agency recommended that strontium ranelate remain available with restrictions relative to patients with existing heart disease. In 2017, a large study of over 280,000 British and Spanish patients found no increased risk of venous thromboembolism in users of strontium ranelate compared to alendronate. Servier ceased manufacturing the drug and in 2019, the drug returned the market in the United Kingdom under the name strontium ranelate Aristo.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.